Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2015

01-04-2015 | Research Article

Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells

Authors: J. Zuo, C. Zhang, C. Ren, D. Pang, Y. Li, X. Xie, Z. Tang, X. Jiang

Published in: Clinical and Translational Oncology | Issue 4/2015

Login to get access

Abstract

Objectives

A variety of inflammatory cytokines have been demonstrated to participate in tumorigenesis and progression. Secretory leukocyte protease inhibitor (SLPI) has been demonstrated to show a broad-spectrum of anti-inflammatory effects. This study investigates the expression of SLPI in human pancreatic cancer tissues and cells as well as its biological effects in human pancreatic cancer cells.

Methods

Reverse transcription-polymerase chain reaction, immunohistochemistry, and Western blot were used to detect SLPI mRNA and protein levels in human pancreatic cancer tissues, adjacent tissues, and pancreatic cancer Bxpc-3 and Panc-1 cells. Knockout of SLPI expression was established by recombinant viral vector expressing short hairpin RNA (shRNA) targeting SLPI. Cell viability was analyzed by MTT assay. Cell apoptosis was detected by Hochest33258 staining and flow cytometry assay.

Results

Higher SLPI expression was observed in pancreatic tissues, Bxpc-3 cells, and Panc-1 cells compared to the peritumoral tissues (p < 0.01). SLPI expression in Bxpc-3 and Panc-1 cells was effectively silenced by shRNA (p < 0.001). Silencing of SLPI expression significantly reduced cell viability, inhibited cell proliferation, and induced cell apoptosis (p < 0.001).

Conclusions

Abnormal over-expression of SLPI in pancreatic cancer cells may be associated with the development of disease through its roles in promoting cancer cell survival and proliferation as well as anti-apoptosis. SLPI can be used as a target for developing targeted therapy of pancreatic cancer.
Literature
1.
2.
Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6:450–3.CrossRefPubMed
3.
Hamada S, Masamune A, Shimosegawa T. Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol. 2014;49:605–17.CrossRefPubMed
4.
Shrikhande SV, Barreto G, Koliopanos A. Pancreatic carcinogenesis: the impact of chronic pancreatitis and its clinical relevance. Indian J Cancer. 2009;46:288–96.CrossRefPubMed
5.
Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, et al. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. Epidemiol Biomark Prev. 2013;22:1730–5.CrossRef
6.
Hritz I, Kuester D, Vieth M, Herszenyi L, Stolte M, Roessner A, et al. Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of helicobacter pylori infection. Eur J Gast Roenterol Hepatol. 2006;18:277–82.CrossRef
7.
Antoniades CG, Khamri W, Abeles RD, Taams LS, Triantafyllou E, Possamai LA, et al. Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. Hepatology. 2014;59:1564–76.CrossRefPubMed
8.
Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med. 2000;6:1147–53.CrossRefPubMed
9.
Choi BD, Jeong SJ, Wang G, Park JJ, Lim DS, Kim BH, et al. Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells. Int J Mol Med. 2011;28:527–34.PubMed
10.
Lin AL, Johnson DA, Stephan KT, Yeh CK. Salivary secretory leukocyte protease inhibitor increases in HIV infection. J Oral Pathol Med. 2004;33:410–6.CrossRefPubMed
11.
Antoniades CG, Khamri W, Abeles RD, Taams LS, Triantafyllou E, Possamai LA, et al. Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. Hepatology. 2014;59:1564–76.CrossRefPubMed
12.
Yang JX, Zhu J, Sun DX, Ding AH. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim Biophys Acta. 2005;1745:310–7.CrossRefPubMed
13.
Ma G, Teresa GW, Kejian L, Jin W, Jennifer S, Neil H, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2014;200:1337–46.CrossRef
14.
Reviglio VE, Sambuelli RH, Olmedo A, Falco M, Echenique J, O’Brien TP, et al. Secretory leukocyte protease inhibitor is an inducible antimicrobial peptide expressed in Staphylococcus aureus endophthalmitis. Mediat Inflamm. 2007;2007:93857.CrossRef
15.
Zhang X, Lee TH, Davidson C, Lazarus C, Wetsel WC, Ellinwood EH. Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. Neuropsychopharmacology. 2007;32:377–87.CrossRefPubMed
16.
Shi Y, Hogue J, Dixit D, Koh J, Olson JA Jr. Functional and genetic studies of isolated cells from parathyroid tumors reveal the complex pathogenesis of parathyroid neoplasia. Proc Natl Acad Sci USA. 2014;111:3092–7.CrossRefPubMedCentralPubMed
17.
Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819–26.PubMed
18.
Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM, et al. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis. 2008;29:466–72.CrossRefPubMed
19.
Nakamura K, Takamoto N, Hongo A, Kodama J, Abrzua F, Nasu Y, et al. Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer. Oncol Rep. 2008;19:1085–91.PubMed
20.
Devoogdt N, Rasool N, Hoskins E, Simpkins F, Tchabo N, Kohn EC. Over-expression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci. 2009;100:434–40.CrossRefPubMedCentralPubMed
21.
Choi BD, Jeong SJ, Wang G, Park JJ, Lim DS, Kim BH, et al. Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells. Int J Mol Med. 2011;28:527–34.PubMed
22.
Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA. 2003;100:5778–82.CrossRefPubMedCentralPubMed
Metadata
Title
Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells
Authors
J. Zuo
C. Zhang
C. Ren
D. Pang
Y. Li
X. Xie
Z. Tang
X. Jiang
Publication date
01-04-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1232-4

Other articles of this Issue 4/2015

Clinical and Translational Oncology 4/2015 Go to the issue

Research Article

A study comparing two consecutive historical periods in breast cancer with a focus on surgical treatment, loco-regional recurrence, distant metastases and mortality

Research Article

Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma

Educational Series – Red Series

Preventive treatments for breast cancer: recent developments

Research Article

CC genotype of anti-apoptotic gene BCL-2 (−938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer

Clinical Guides in Oncology

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Research Article

Overexpression of ribonuclease inhibitor defines good prognosis and suppresses proliferation and metastasis in human colorectal cancer cells via PI3K/AKT pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits